Opportunistic CT Bone Density Screening Improves Osteoporosis Screening Rate
By Elana Gotkine HealthDay Reporter
MONDAY, March 10, 2025 -- Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs, according to a study published in the March issue of the Journal of the American College of Radiology.
Soterios Gyftopoulos, M.D., from NYU Langone Health in New York City, and colleagues extracted data from the Medicare 5 Percent Research Identifiable Files (2015 to 2022) to examine the potential impact of opportunistic CT bone density screening.
The analysis included 2,897,040 beneficiaries, of whom 20.2 percent underwent dual-energy X-ray absorptiometry (DEXA), and 22.7 percent did not undergo DEXA but did undergo at least one CT scan that included the L1 vertebral body (67.8 and 32.2 percent without and with contrast, respectively). The researchers found that within one year of CT, there were 2,766 and 613 (0.6 and 0.3 percent) hip and 23,889 and 5,222 (5.3 and 2.5 percent) spine fragility fractures in the noncontrast and contrast CT groups, respectively. The osteoporosis screening rate would increase by 76 and 113 percent using only noncontrast CT studies and all CT studies, respectively. This study population would see a medical cost avoidance in excess of $17 million if only noncontrast CT was used to identify osteoporosis and treatment was successfully implemented in 100 percent of eligible beneficiaries. Potential annual cost avoidance for this study's population would be nearly $100 million, and it would be $2.5 billion for all 2023 Medicare fee-for-service beneficiaries if any CT was used.
"These findings provide additional support for incorporating opportunistic CT imaging into daily clinical practice," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-11 06:00
Read more

- FDA Grants Orphan Drug Designation for Bexmarilimab in MDS
- At-Home Light-Emitting Diode Devices Safe, Effective for Acne Treatment
- Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer
- Four in 10 Adults With Chronic Pain Report Depression, Anxiety
- Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order
- Proportion of Pediatric Fatalities From Weather Events Increasing
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions